Document is current
Any future updates will be listed below
-
Authors
Mezzanotte-Sharpe, Jessica
ONeill, Anne
Mayer, Ingrid A.
Arteaga, Carlos L.
Yang, Ximing J.
Wagner, Lynne I.
Cella, David
Meropol, Neal J.
Alpaugh, R. Katherine
Saphner, Thomas J.
Swaney, Robert E.
Hoelzer, Karen L.
Gradishar, William J.
Abramson, Vandana G.
Sundaram, P. Kothai
Jilani, Shamim Z.
Perez, Edith A.
Lin, Nancy U.
Jahanzeb, Mohammad
Wolff, Antonio C.
Sledge, George W.
Reid, Sonya A.
-
Funding
Funding for this research was provided by:
National Cancer Institute (UG1CA233270, UG1CA233270, UG1CA233302, UG1CA233320, UG1CA189828, UG1CA233320, UG1CA190140, UG1CA189805, UG1CA189830, UG1CA233320, UG1CA233270, UG1CA189954, U10CA180821, U10CA180821, U10CA180821, U10CA180888, UG1CA233196, UG1CA233270)
Center for Cancer Research (UG1CA233234)
- License Information
-
More Information
Article History
Received: 19 April 2024
Accepted: 23 June 2024
First Online: 5 July 2024
Declarations
:
: JMS, AON, TJS, WJG, EAP, and ACW have no conflicts of interest related to this project. CLA has served as scientific advisor to Novartis, Lilly, Merck, Immunomedics, Daiichi Sankyo, AstraZeneca, PUMA Biotechnology, TAIHO Oncology, OrigiMed, Arvinas, Sanofi, and the Susan G. Komen Foundation. He has received grant support from Pfizer, Lilly, and Takeda. NJM is an employee of Flatiron Health, Inc. an independent member of the Roche group, and reports stock ownership in Roche. VGA has served as a scientific advisor for GuardantHealth and Astra Zeneca and has research funding support from Genetech, Bayer, and GuardantHealth. NUL declares consulting honorarium from Seagen, Daichii-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., Eisai; travel support from Olema Pharmaceuticals; research support (to institution) from Genentech, Zion Pharmaceuticals (as part of GNE), Pfizer, Seagen, Merck, Olema Pharmaceuticals, AstraZeneca; royalties from Up To Date. SAR has served as a consultant for Daiichi-Sankyo, Astra Zeneca, Novartis, and Gilead.
: Written informed consent was obtained from all patients before enrollment, in agreement with approved protocols from respective ethics committees at every site.
